Cell-free DNA and genetic testing company Natera Inc (NASDAQ: NTRA) announced on Monday that it has introduced the Prospera Heart test with Donor Quantity Score (DQS), improving the detection of rejection in heart transplant patients. This new feature enhances the ability to detect both acute cellular rejection (ACR) and antibody-mediated rejection (AMR).
Traditional donor-derived cell-free DNA (dd-cfDNA) tests rely on the percentage of dd-cfDNA in the blood, which can be affected by unrelated factors like infection or chemotherapy. The new DQS technique normalises these fluctuations by incorporating a second metric. Prospera Heart with DQS combines the traditional donor fraction and the DQS into a two-threshold algorithm, providing a more accurate risk assessment.
A study conducted at the University of Utah and the University of California San Diego demonstrated that incorporating DQS improves the performance of Prospera Heart in screening for biopsy-proven active rejection. In an analysis of 703 plasma samples, the sensitivity increased from 80.0% to 88.2%, specificity from 76.1% to 84.2%, and the negative predictive value (NPV) from 97.4% to 98.6%, reducing false positives by 37.5%.
These findings were presented at the International Society for Heart and Lung Transplantation's annual meeting in April 2024 and will be submitted for peer-reviewed publication.
The company has successfully applied a similar two-threshold approach in kidney transplant rejection tests with Prospera Kidney, published in the Journal of the American Society of Nephrology. The Prospera tests use single-nucleotide (SNP)-based massively multiplexed PCR (mmPCR) technology to identify allograft rejection non-invasively, without needing prior donor or recipient genotyping.
Natera focuses on oncology, women's health and organ health. The company operates ISO 13485-certified and CAP-accredited laboratories in Austin, Texas and San Carlos, California.
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
PureTech Health highlights progress in IPF research and LYT-100 at CHEST 2024
MediLink enters clinical trial collaboration and supply agreement with Amgen
Innovent Biologics partners with Jiangsu Aosaikang Pharmaceutical for lung cancer treatment
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
hVIVO reports positive results from RSV antiviral human challenge trial
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Liquidia and Pharmosa expand collaboration for inhaled treprostinil
Alvotech launches confirmatory study for Entyvio biosimilar
Merck's KEYTRUDA receives new approvals in Japan for lung and urothelial cancers
Innate Pharma receives FDA clearance of IND for IPH4502, a Nectin-4 targeting ADC for solid tumours
Intas Pharmaceuticals reports positive opinion for HETRONIFLY in Europe
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial